- Acquisition of own shares pursuant to the provision of its Articles of Incorporation in accordance with Article 459, paragraph 1 of the Companies Act and cancellation of treasury stock pursuant to the provisions of Article 178 of the Companies Act-

TOKYO, March 10, 2022  - Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) today announced the status and the completion of acquisition of its own shares based on the resolution of the Board of Directors' meeting held on February 2, 2022, pursuant to the Articles of Incorporation in accordance with Article 459, paragraph 1 of the Companies Act.

The Company also announced the number of shares to be canceled on March 29, 2022 pursuant to Article 178 of the Companies Act has been finalized.

Particulars

  1. Status of acquisition of own shares
    (1)    Class of shares acquired:    Common stock of the Company
    (2)    Total number of shares acquired:    11,096,700 shares
    (3)    Total amount of acquisition cost:    20,642,021,200 yen
    (4)    Period of acquisition:    From March 1, 2022 to March 9, 2022
    (5)    Method of acquisition:    Purchased on the Tokyo Stock Exchange
     
  2. Details of the cancellation of treasury stock
    (1)    Class of shares to be cancelled:    Common stock of the Company
    (2)    Number of shares to be cancelled:    25,935,500 shares
            (Ratio to the total number of shares outstanding [excluding treasury stock]: 1.40%)
    (3)    Cancellation date:    March 29, 2022
     

(Reference)

  1. Details of the resolution at the meeting of the Board of Directors on February 2, 2022
    (1)    Class of shares to be acquired:    Common stock of the Company
    (2)    Total number of shares to be acquired:    Up to 29 million shares
            (Ratio to the total number of shares outstanding [excluding treasury stock): 1.57%]
    (3)    Total amount of acquisition cost:    Up to 50 billion yen
    (4)    Period of acquisition:    From February 3, 2022 to March 24, 2022
     
  2.  Accumulated Company’s own shares acquired pursuant to the above board resolution
    (1)    Total number of shares acquired:    25,935,500 shares
    (2)    Total amount of acquisition cost:    49,999,849,800 yen 
            (Ratio to the total number of shares outstanding [excluding treasury stock]: 1.40%)
     
  3. Details of the decided cancellation of treasury stock (February 2, 2022)
    (1)    Class of shares to be cancelled:    Common stock of the Company
    (2)    Total number of shares to be cancelled:    All of the shares repurchased as stated in 2 above
    (3)    Scheduled cancellation date:    March 29, 2022
     
  4. Status of shares after cancellation
    (1)    Number of shares issued:    1,835,851,575 shares (expected)
    (2)    Number of the Company’s treasury stock:    8,845,998 shares (expected)
            [Estimated numbers of shares described above (1) and (2) were calculated on the basis of the issued shares and the Company’s treasury stock as of February 28, 2022, respectively.]

 

Click below for a copy of the full press release

Contact the Media Relations team
Corporate Advocacy & Relations
Main phone line for Media: +81-3244-3201 
Business hours (JST)
From Monday to Thursday: 8:45 am to 5:45 pm, Friday: 8:45 am to 4:00 pm
(closed on Saturdays, Sundays, national holidays and company holidays)